Developer · Germany
Boehringer Ingelheim International GmbH
Boehringer Ingelheim is a research-driven pharmaceutical company headquartered in Ingelheim am Rhein, Germany, developing human and animal health medicines. It is one of the world's largest privately held (family-owned) pharmaceutical companies, with a CNS pipeline spanning schizophrenia and mood disorders.
Pipeline (3)
- Major depressive disorderPhase 2Completed
- Major depressive disorderDiscontinuedDiscontinued
- SchizophreniaDiscontinuedDiscontinued
Catalysts · 0 upcoming · 4 reported
Recently reported
- 2025-12-01missed
Iclepertin (BI 425809)forSchizophreniaFull results
Pooled CONNEX Phase 3 results published in The Lancet Psychiatry: iclepertin no better than placebo on MCCB (p=0.63).
- 2025-01-16missed
Iclepertin (BI 425809)forSchizophreniaTopline data
Phase 3 CONNEX (CONNEX-1/-2/-3) missed primary (MCCB) and key secondary endpoints; iclepertin development in schizophrenia discontinued.
- 2024-01-10missed
BI 1358894forMajor depressive disorderFull results
BI 1358894 Phase 2 dose-ranging trial in MDD negative: no separation from placebo on MADRS at week 6
- 2022-04-19terminated
BI 1358894forMajor depressive disorderFull results
Decentralized BI 1358894 MDD trial terminated for deficient enrollment (45 of target randomized)
Recent activity
- Dec 1, 2025ReadoutIclepertin (BI 425809)·SchizophreniamissedPooled CONNEX Phase 3 results published in The Lancet Psychiatry: iclepertin no better than placebo on MCCB (p=0.63).source ↗
- May 2, 2025Phase changeBI 1569912·Major depressive disorderPhase 2Phase 2 monotherapy dose-finding trial (NCT06558344) reached primary completion.source ↗
- Feb 26, 2025Phase changeBI 1569912·Major depressive disorderPhase 2Phase 2 adjunctive dose-finding trial (NCT06280235) reached primary completion.source ↗
- Jan 16, 2025ReadoutIclepertin (BI 425809)·SchizophreniamissedPhase 3 CONNEX (CONNEX-1/-2/-3) missed primary (MCCB) and key secondary endpoints; iclepertin development in schizophrenia discontinued.source ↗
- Jan 10, 2024ReadoutBI 1358894·Major depressive disordermissedBI 1358894 Phase 2 dose-ranging trial in MDD negative: no separation from placebo on MADRS at week 6source ↗
- Apr 19, 2022ReadoutBI 1358894·Major depressive disorderterminatedDecentralized BI 1358894 MDD trial terminated for deficient enrollment (45 of target randomized)source ↗
- Aug 9, 2021Phase changeIclepertin (BI 425809)·SchizophreniaPhase 3Phase 3 CONNEX program initiated (CONNEX-1/-2/-3 plus the CONNEX-X open-label extension); iclepertin 10 mg once daily over 26 weeks adjunctive to stable antipsychotic treatment.source ↗
- Jun 25, 2020Phase changeIclepertin (BI 425809)·SchizophreniaPhase 2Phase 2 proof-of-concept (NCT02832037, n=509, 12 weeks) reported: iclepertin was well tolerated and significantly improved cognition (MCCB) vs placebo in CIAS, supporting Phase 3.source ↗
Trials recruiting · 1 recruiting of 60 sponsored
- Phase 1BI 3031185, Placebo
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
Competitive landscape
Other companies developing against Boehringer Ingelheim International GmbH's targets or indications.
- Neurocrine Biosciences, Inc.5 compoundsGluN2BMajor depressive disorderSchizophrenia
- Alto Neuroscience, Inc.3 compoundsMajor depressive disorderSchizophrenia
- Cerevel Therapeutics Holdings, Inc.2 compoundsMajor depressive disorderSchizophrenia
- Intra-Cellular Therapies, Inc.1 compoundMajor depressive disorderSchizophrenia
- LB Pharmaceuticals Inc.1 compoundMajor depressive disorderSchizophrenia
- Syndeio Biosciences, Inc.2 compoundsGluN2BMajor depressive disorder
- Vanda Pharmaceuticals Inc.2 compoundsMajor depressive disorderSchizophrenia
- Alkermes plc1 compoundSchizophrenia
- Autobahn Therapeutics, Inc.1 compoundMajor depressive disorder
- Axsome Therapeutics, Inc.1 compoundMajor depressive disorder
- Beckley Psytech Limited1 compoundMajor depressive disorder
- Biohaven Ltd.1 compoundMajor depressive disorder